Investigational drug · Phase 2
CSG452
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NASH.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "CSG452"
First trial start
2022
Nov 14, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CSG452", any sponsor or status.
Conditions studied
As listed on its trial records.
- NASH
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "CSG452" as an intervention, largest first.
- Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver FibrosisPivotal-lookingCompleted
Kowa Research Institute, Inc.Industry
NCT05327127 · 228 participants · Start Nov 14, 2022 · Primary completion May 20, 2026
Drug: K-877-ER; CSG452 and 1 more · For: NASH
Sites: Tucson, Arizona; Little Rock, Arkansas; Lincoln, California · 77 sites in all
- TOFO Insulin Combination TrialPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02201004 · 211 participants · Start Jun 2014 · Primary completion Jan 2016
Drug: TOFOGLIFLOZIN CSG452; insulin and 1 more · For: Type 2 Diabetes Mellitus
Sites: Adachi-ku, Japan; Atsugi-shi, Japan; Chuoh-ku, Japan · 30 sites in all
Kowa Research Institute, Inc.Industry
NCT05722262 · 30 participants · Start Feb 24, 2023 · Primary completion Apr 1, 2023
Drug: K-001; K-877-ER and 1 more · For: Healthy
Sites: Austin, Texas
- Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult VolunteersCompleted
Kowa Research Institute, Inc.Industry
NCT04237597 · 20 participants · Start Dec 17, 2019 · Primary completion Jan 31, 2020
Drug: K-877; CSG452 · For: Healthy
Sites: Austin, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
Kaku K, Watada H, Iwamoto Y, et al. · Cardiovasc Diabetol 2014
- Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Ohtake Y, Sato T, Kobayashi T, et al. · J Med Chem 2012
- Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
Suzuki M, Honda K, Fukazawa M, et al. · J Pharmacol Exp Ther 2012
Also in development for NASH
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.